Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Clinical evidence

Panorama

87 evidence topics · 21 sources

Objective
Location and study date
Study dates in the registry
MilestoneRegistry record
Study start (actual)“2025-01-29”
Primary completion (actual)“2026-08-13”
Study completion (estimated)“2027-05”
First posted“2025-02-05”
Last update posted“2026-09-04”
EU member state decision, trial start, and recruitment dates
Topline timing: second half of 2026, January 2025, superseded in April 2026
Study design
Eligibility criteria
Treatment
Single dose in Part A
Study outcomes
Rationale for using hamilton anxiety rating scale total score as the primary endpoint
Other registered secondary outcomes in Part A

“HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period” (opens the source at this quote in a new tab)

“HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period” (opens the source at this quote in a new tab)

“Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period” (opens the source at this quote in a new tab)

“Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score” (opens the source at this quote in a new tab)

“Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score” (opens the source at this quote in a new tab)

“Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)” (opens the source at this quote in a new tab)

“Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)” (opens the source at this quote in a new tab)

“Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period” (opens the source at this quote in a new tab)

Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry
FieldRegistry record
Enrollment (actual)“245”
Planned maximum in the detailed description“The study will enroll up to 375 participants aged 18 to 74 years”
Planned enrollment: approximately 250 participants, January 2025, superseded in April 2026
Description of analysis sets
Results
Participant disposition
Part B enrollment in the extension population
Part A groupParticipants
DT120 ODT 100 µg“n=62”
DT120 ODT 50 µg control“n=33”
Placebo ODT“n=68”
Total“n=163”
Baseline characteristics
Demographics and baseline characteristics, ITT population
CharacteristicDT120 ODT 100 µg (n=96)DT120 ODT 50 µg control (n=52)Placebo ODT (n=97)Overall (n=245)
Mean age (years)“39.8”“40.4”“42.3”“40.9”
Sex (% female)“62%”“56%”“62%”“60%”
Race (% white)“82%”“85%”“84%”“83%”
Baseline HAM-A score, mean (SD)“28.3 (5.5)”“27.7 (4.8)”“28.0 (5.6)”“28.0 (5.4)”
Baseline CGI-S score, mean (SD)“4.7 (0.5)”“4.7 (0.6)”“4.7 (0.6)”“4.7 (0.6)”
Past use of any psychedelic, n (%)“11 (12%)”“8 (15%)”“16 (17%)”“35 (14%)”
Past use of LSD, n (%)“4 (4%)”“4 (8%)”“8 (8%)”“16 (7%)”
Disease severity, treatment history, and comorbidity, ITT population
CharacteristicDT120 ODT 100 µg (n=96)DT120 ODT 50 µg control (n=52)Placebo ODT (n=97)Overall (n=245)
HAM-A moderate (<24), n (%)“20 (21%)”“9 (17%)”“27 (28%)”“56 (23%)”
HAM-A severe (≥24), n (%)“76 (79%)”“43 (83%)”“70 (72%)”“189 (77%)”
No past GAD treatments, n (%)“29 (30%)”“14 (27%)”“17 (18%)”“60 (25%)”
One past GAD treatment, n (%)“20 (21%)”“15 (29%)”“22 (23%)”“57 (23%)”
Two or more past GAD treatments, n (%)“47 (49%)”“23 (44%)”“58 (60%)”“128 (52%)”
Comorbid MDD, n (%)“28 (29%)”“17 (33%)”“25 (26%)”“70 (29%)”
MADRS score, mean (SD)“13.3 (4.4)”“13.4 (4.5)”“13.5 (3.9)”“13.4 (4.2)”
Years since diagnosis of GAD, mean (SD)“6.9 (7.6)”“9.4 (11.4)”“9.9 (8.8)”“8.6 (9.0)”
Years since onset of GAD symptoms, mean (SD)“16.4 (12.6)”“18.2 (15.5)”“19.1 (13.4)”“17.8 (13.6)”
Characteristics at Part B entry
CharacteristicDT120 ODT 100 µg (n=62)DT120 ODT 50 µg control (n=33)Placebo ODT (n=68)Total (n=163)
Mean age (years)“39.5”“42.3”“42.8”“41.4”
Sex, female (%)“62.9%”“51.5%”“58.8%”“58.9%”
Race (% white)“82.3%”“87.9%”“83.8%”“84.0%”
HAM-A score at Part B entry“18.3”“21.6”“23.3”“21.1”
CGI-S score at Part B entry“3.7”“4.0”“4.2”“4.0”
Efficacy results
Primary, key secondary, and other secondary endpoints
EndpointDT120 ODT 100 µgPlacebo ODTPlacebo-adjusted difference
HAM-A: LS mean change at Week 12 (primary)“-9.8”“-4.7”“-5.1 (p<0.0001)”
CGI-S: LS mean change at Week 12 (key secondary)“-1.0”“-0.5”“-0.6 (p<0.0001)”
HAM-A: LS mean change at Week 1 (key secondary)“-9.8”“-4.5”“-5.3 (p<0.0001)”
CGI-S: LS mean change at Day 2 (key secondary)“-1.1”“-0.3”“-0.8 (p<0.0001)”
HAM-A response rate (≥50%) at Week 12“32%”“14%”“18% (p<0.05)”
HAM-A remission rate (≤7) at Week 12“15%”“4%”“12% (p<0.05)”
HAM-A mild or better (<16) at Week 12“35%”“17%”“19% (p<0.01)”
HAM-A change by visit, 100 µg and 50 µg arms
Visit100 µg: change from baseline50 µg: change from baseline100 µg: improvement over placebo50 µg: improvement over placebo
Week 1“-9.8”“-10.3”“-5.3”“-5.8”
Week 4“-12.3”“-8.8”“-7.0”“-3.5”
Week 8“-10.4”“-8.1”“-5.3”“-3.0”
Week 12“-9.8”“-8.3”“-5.1”“-3.6”
CGI-S change by visit, 100 µg and 50 µg arms
Visit100 µg: change from baseline50 µg: change from baseline100 µg: improvement over placebo50 µg: improvement over placebo
Day 2“-1.1”“-1.1”“-0.8”“-0.8”
Week 1“-1.2”“-1.3”“-0.7”“-0.8”
Week 4“-1.4”“-1.2”“-1.0”“-0.7”
Week 12“-1.1”“-0.9”“-0.6”“-0.4”
Odds ratios for response, remission, and mild or better at Week 12
Outcome at Week 12Odds ratio, DT120 ODT 100 µg vs placebo
Response (HAM-A ≥ 50% improvement)“Odds ratio: 2.9”
Remission (HAM-A ≤ 7)“Odds ratio: 4.2”
Mild or better (HAM-A < 16)“Odds ratio: 2.6”
Pooled standard deviation of the primary endpoint
ItemPanorama
Primary endpoint, DT120 vs placebo“-5.1”
Design“3 arms”
Baseline HAM-A“28.0”
Baseline MADRS“13.4”
Pooled endpoint SD“8.4”
Health-related quality of life and patient-reported outcomes
Results of patient-reported outcomes

No evidence found.

Safety results
TEAEs with incidence of 10% or more in the 100 µg arm, on and after dosing day
TEAEDosing day: 100 µg (n=96)Dosing day: 50 µg (n=51)Dosing day: placebo (n=97)After dosing day: 100 µg (n=96)After dosing day: 50 µg (n=51)After dosing day: placebo (n=97)
Illusion“65 (68%)”“31 (61%)”“12 (12%)”“3 (3%)”“0”“0”
Nausea“35 (37%)”“13 (26%)”“4 (4%)”“2 (2%)”“4 (8%)”“1 (1%)”
Headache“23 (24%)”“14 (28%)”“13 (13%)”“13 (14%)”“6 (12%)”“10 (10%)”
Euphoric mood“30 (31%)”“16 (31%)”“5 (5%)”“1 (1%)”“0”“0”
Fatigue“22 (23%)”“5 (10%)”“6 (6%)”“7 (7%)”“1 (2%)”“4 (4%)”
Dizziness“22 (23%)”“10 (20%)”“3 (3%)”“1 (1%)”“1 (2%)”“0”
Anxiety“16 (17%)”“7 (14%)”“7 (7%)”“6 (6%)”“3 (6%)”“5 (5%)”
Crying“20 (21%)”“6 (12%)”“0”“0”“1 (2%)”“0”
Feeling cold“14 (15%)”“2 (4%)”“6 (6%)”“0”“0”“1 (1%)”
Paraesthesia“13 (14%)”“4 (8%)”“3 (3%)”“0”“1 (2%)”“1 (1%)”
Time perception altered“13 (14%)”“4 (8%)”“1 (1%)”“0”“0”“0”
Feeling of relaxation“12 (13%)”“8 (16%)”“11 (11%)”“1 (1%)”“0”“0”
Inappropriate affect“12 (13%)”“4 (8%)”“0”“0”“0”“0”
Feeling hot“11 (12%)”“4 (8%)”“4 (4%)”“0”“0”“0”
Emotional disorder“8 (8%)”“3 (6%)”“3 (3%)”“3 (3%)”“0”“0”
Feeling abnormal“10 (10%)”“7 (14%)”“4 (4%)”“0”“0”“1 (1%)”
Restlessness“10 (10%)”“1 (2%)”“3 (3%)”“1 (1%)”“0”“1 (1%)”
Tremor“10 (10%)”“4 (8%)”“1 (1%)”“1 (1%)”“0”“0”
Study limitations
Summary

Panorama randomized 245 participants 2:1:2 to a single dose of DT120 ODT 100 µg (96), DT120 ODT 50 µg (52), or placebo (97), and its primary analysis compares the 100 µg arm with placebo only. The 50 µg arm was not designed or powered for statistical comparisons, so the placebo-adjusted changes of -3.5 at Week 4 and -3.6 at Week 12 in that arm, and the dose-response statements built on them, carry no hypothesis test. The primary endpoint difference of -5.1 points (d=0.64) exceeds the 2.5-point minimal clinically important difference used in the phase 2b trial and the sponsor's 4-point target product profile; in the presentation's comparison of its trials, Panorama had a pooled endpoint standard deviation of 8.4. The study had no active comparator.

The 50 µg arm was included to mitigate functional unblinding, yet 91% (50 µg) and 95% (100 µg) of participants correctly guessed assignment to drug; no placebo-arm guess rate was reported. HAM-A ratings were made by central raters blinded to treatment assignment and visit number, and FDA guidance states that functional unblinding can lead to expectation bias. The sponsor states that the results support the conclusion that the dose response is not attributable to functional unblinding.

The results come from sponsor topline disclosures (an announcement, a slide presentation, and a Form 10-Q), the registry record lists no results posted, and one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results. These disclosures report no confidence intervals for the primary or key secondary endpoints. Response, remission, and mild-or-better rates (32% vs 14%, 15% vs 4%, 35% vs 17%) are other secondary endpoints outside the multiplicity-controlled key secondary endpoints. Subgroup analyses cover the 100 µg and placebo arms only, and the presentation states that small subgroups give unstable estimates. Patient-reported, functional, quality of life, and sexual functioning outcomes (PGI-S, WPAI-SHP, EQ-5D-5L, CSFQ-14) are registered but unreported.

Part B results come from an interim analysis as of August 11, 2026, based on partial data and subject to change, with open-label dosing and declining numbers of participants (87 at Week 12 and 27 at Week 28 in the response analysis); the 50 µg cohort was excluded for small numbers. The presentation reports two Part B denominators, 204 participants entering Part B (76, 42, and 86 by Part A group) and an extension population of 163 (62, 33, and 68), without stating how they differ. The sponsor states that Part B safety data are expected in a future presentation.

The enrolled population was 60% female and 83% white, aged 18 to 74 years, excluded a current major depressive episode, substance use disorder, and psychotic or bipolar disorder in the participant or a first-degree relative, and excluded systematic psychotherapy within 4 weeks before screening. The psychedelic use exclusion was later amended to any lifetime use; 35 participants (14%) reported past use of any psychedelic and 16 (7%) past use of LSD. Treatment history differed between arms: 60% of placebo participants and 49% of 100 µg participants had two or more past GAD treatments. Enrollment exceeded the target of 200 participants set after a blinded sample size re-estimation. The company reports approximately 32 study centers while the registry lists 36 locations. Participants were monitored for at least 8 hours on dosing day, and 94% of the 100 µg arm met end-of-session checklist criteria by hour 8. The methods report states that Definium Therapeutics funded the study and that all of its authors are company employees.